Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Gastrointestinal 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 772Leukemia 596Leukemia, Lymphocytic, Chronic, B-Cell 535Precursor Cell Lymphoblastic Leukemia-Lymphoma 485Myelodysplastic Syndromes 408Lymphoma, Non-Hodgkin 265Lymphoma 265Hematologic Neoplasms 251Leukemia, Myelogenous, Chronic, BCR-ABL Positive 232Multiple Myeloma 199Hodgkin Disease 193Lymphoma, Follicular 181Lymphoma, Mantle-Cell 179Lymphoma, B-Cell, Marginal Zone 156Lymphoma, Large B-Cell, Diffuse 155Burkitt Lymphoma 155Recurrence 149Leukemia, Myelomonocytic, Chronic 139Congenital Abnormalities 131Myeloproliferative Disorders 122Waldenstrom Macroglobulinemia 106Neoplasms 97Leukemia, Myeloid, Chronic-Phase 97Lymphoma, Large-Cell, Immunoblastic 91Primary Myelofibrosis 88Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 81Blast Crisis 80Leukemia, Myeloid, Accelerated Phase 74Anemia, Refractory, with Excess of Blasts 72Lymphoma, T-Cell, Cutaneous 68

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Turcot syndrome × Other hematologic neoplasm × Clear all
NCT04439214 2021-04-06

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

National Cancer Institute (NCI)

Phase 2 Completed
47 enrolled 10 charts
LymphoidOther hematologic neoplasmPlasma cell

Turcot syndrome, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡